10.1074/jbc.M211926200 20 BendallJ
Acknowledgements Medical writing and editorial support were provided by Nicole Cash, PhD, and Abbey Pearson, MSci, of Axis, a division of Spirit Medical Communications Group Limited (and were funded by Novo Nordisk Inc.) in accordance with Good Publication Practice 3 (GPP3) guidelines ( Declarations Funding This trial and medical writing support for the publication were funded by Novo Nordisk A/S, Sborg, Denmark
Jonathan Zontag , lead study author and a researcher at Hebrew University
Supplementary information Supplementary Table 1 Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made
KRAVITZ How is the KLOwen system different from Ormcos Insignia, ** which was developed in the early 2000s
For many patients, the effectiveness of oral Wegovy matches that of its injectable counterpart
